Page 5 - Nasdaq Cccc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq cccc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Cccc Today - Breaking & Trending Today

C4 Therapeutics, Inc. (NASDAQ:CCCC) Forecasted to Post FY2023 Earnings of ($2.84) Per Share

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) – Stock analysts at HC Wainwright cut their FY2023 EPS estimates for C4 Therapeutics in a report released on Monday, May 8th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($2.84) for the year, down from their previous estimate of […] ....

United States , Lazard Asset Management , Morgan Stanley , Jpmorgan Chase Co , Ensign Peak Advisors Inc , Credit Suisse Group , Therapeutics Inc , Principal Financial Group Inc , Sohn Co , Get Rating , Suisse Group , Stock Down , Point Capital Management , Asset Management , Peak Advisors Inc , Principal Financial Group , C4 Therapeutics , Nasdaq Cccc , Earnings Estimates , Hc Wainwright ,

HC Wainwright Trims C4 Therapeutics (NASDAQ:CCCC) Target Price to $25.00

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price objective decreased by HC Wainwright from $35.00 to $25.00 in a research report sent to investors on Monday, The Fly reports. HC Wainwright also issued estimates for C4 Therapeutics’ FY2023 earnings at ($2.84) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.42) EPS, FY2026 earnings […] ....

Hong Kong , United States , Jpmorgan Chase Co , Morgan Stanley , Ensign Peak Advisors Inc , Therapeutics Inc , Hong Kong Ltd , Lazard Asset Management , Tower Research Capital , Credit Suisse Group , Get Rating , Suisse Group , Kong Ltd , Asset Management , Peak Advisors Inc , Research Capital , C4 Therapeutics , Nasdaq Cccc , Lower Price Target , Hc Wainwright ,

Contrasting C4 Therapeutics (NASDAQ:CCCC) & Voyager Therapeutics (NASDAQ:VYGR)

C4 Therapeutics (NASDAQ:CCCC – Get Rating) and Voyager Therapeutics (NASDAQ:VYGR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations. Institutional and Insider Ownership 80.3% of C4 Therapeutics shares […] ....

United States , United Kingdom , Marka Kay , Krystof Bankiewicz , Phillip Zamore , Calico Life Sciences , Roche Ltd , Therapeutics Inc , Roche Inc , Biogen Ma Inc , Tau Program , Voyager Therapeutics Inc , Get Rating , Voyager Therapeutics , Voyager Therapeutic , Hoffmann La Roche Inc , Guang Ping Gao , C4 Therapeutics , Nasdaq Cccc , Stock Comparison , Stock Analysis ,

C4 Therapeutics (NASDAQ:CCCC) PT Lowered to $25.00 at HC Wainwright

C4 Therapeutics (NASDAQ:CCCC – Get Rating) had its price target lowered by HC Wainwright from $35.00 to $25.00 in a research note published on Monday morning, The Fly reports. HC Wainwright also issued estimates for C4 Therapeutics’ FY2023 earnings at ($2.84) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.42) EPS, FY2026 earnings at […] ....

United States , Morgan Stanley , Credit Suisse Group , Therapeutics Inc , Vanguard Group Inc , Arrowmark Colorado Holdings , Jpmorgan Chase Co , Blackrock Inc , Get Rating , Suisse Group , Mark Colorado Holdings , Street Corp , Vanguard Group , C4 Therapeutics , Nasdaq Cccc , Lower Price Target , Hc Wainwright ,

ageas SA/NV (OTCMKTS:AGESY) Upgraded at ING Group

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) has been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. […] ....

United States , Utpal Koppikar , Swiss National Bank , Metlife Investment Management , Credit Suisse Group , Therapeutics Inc , York Mellon Corp , Securities Exchange Commission , Jpmorgan Chase Co , Morgan Stanley , Get Rating , Suisse Group , Director Utpal Koppikar , Exchange Commission , National Bank , New York Mellon Corp , Life Investment Management , Rhumbline Advisers , C4 Therapeutics , Nasdaq Cccc ,